ENDOCRINOLOGY , Almeida Filho PJ

Abstracts XIX Brazilian Congress of Nuclear Medicine

2. ENDOCRINOLOGY

2.5 - NEW FOLLOW-UP STRATEGY FOR DIFFERENTIATED THYROID CANCER (DTC) USING WHOLE BODY IMAGING WITH TC-99m-SESTAMIBI (WBMIBI)

Almeida Filho PJ, Lemos MR, Freita AC, Almeida CA, Borges Neto, S.

nuclear@elogica.com.br

The purpose of this study was to evaluate the potential of 99mTc-Sestamibi whole body study (WBMIBI) as na alternative to iodine scan for the follow-up of patients with differentiated thyroid carcinoma (DTC). We studied 99 consecutive patients with DTC submitted to total or near total thyroidectomy followed by ablative dose of 131I. Eighty-six were females and mean age was 44 ± 12 years. We performed whole body 99mTc-Sestamibi (WBMIBI) and serum thyroglobulin dosage (TG) at least 6 months after 131I treatment. All individuals were on T4 therapy. From 110 studies WBMIBI and TG. 96% were concordant and only 4% were discordant. From the 27 crosses studies with at least one abnormal result. 16 were compared with whole body iodine study WBI. In 4 cases, the WBI did not reveal functioning thyroid tissue when both TG and WBMIBI indicated tumoral activity. In one case of pulmonary metastasis confirmed by X-ray, with normal TG, both WBMIBI and WBI were positive. We conclude that WBMIBI should be strongly considered as a scintigraphic choice agent on the follow-up of DTC. this technique is able to demonstrate the sites of tumoral activity with optimal image resolution, particularly, in those with abnormal TG and negative WBI and it is also a potentially valuable tool in patients with antibodies anti-TG. The WBI in ablated patients may be considered only for therapy planning.